The mAbs 2D1 did not show neutralizing potential for the viruses at the tested concentrations

The mAbs 2D1 did not show neutralizing potential for the viruses at the tested concentrations. == The protective effects of mAbs in vivo == L67 To test if the mAbs have protective activity in vivo, we assessed the efficacy in prophylaxis and therapy of mAbs against HP001 virus in mice, and we found that 1H10 and 2D1 protect mice from lethal challenge (data not show). To further evaluate the efficacy of mAbs against H7N9, including prophylaxis and therapy, 1H10 and 2D1 were evaluated in a mouse model of HP001. to have haemagglutination inhibition and neutralizing activity on both LP-and HP-H7N9 strains. Further study indicated that the protection provided by 2D1 was mediated by antibody-dependent cellular cytotoxicity. The mAbs described here provide promising results and merit further development into potential antiviral therapeutics for H7N9 L67 infection. KEYWORDS:Influenza virus, H7N9, monoclonal antibody, neutralization, antibody-dependent cellular cytotoxicity (ADCC) == Introduction == Avian influenza virus (AIV) is an enveloped, segmented, negative-strand RNA virus of the Orthomyxoviridae family [1]. The primary host of AIV are birds, but occasionally the virus can breach the species barrier from domestic poultry to humans, such as H5N1, H6N1, H7N3, H7N9, H9N2 and H10N8 [25]. Among these strains, H5N1 and H7N9 infections have received extensive attention due to their alarmingly high mortality rate [6]. The H7N9 virus was first isolated from patients in Tmem10 Eastern China in early 2013 and has been reported to cause five epidemic waves in China [7]. The general clinical manifestations of H7N9 patients are flu-like symptoms, but it is prone to cause acute respiratory distress syndrome or other complications especially in the elderly and children L67 [8]. Up to now, H7N9 has been confirmed cause more than 1500 individual infections with a mortality rate of approximately 40% [9]. In addition, the circulating H7N9 viruses have evolved in these successive waves through mutation accumulation and genomic reassortment [10]. Highly pathogenic (HP) H7N9 viruses were identified in the fifth wave in 2017, and have caused fatal outcomes in China L67 [11]. Control of these viruses remains an important point of concern for global human health. Currently, vaccination remains the most effective measures to reduce morbidity and mortality caused by influenza virus infection [12]. However, there is no commercially available vaccine for H7N9 infection in humans and the primary therapeutic treatments remain supportive medical care and neuraminidase inhibitors (NAIs). Previous studies have shown, NAIs are limited by their short treatment time-window (within 48h after symptom onset) and the emergence of drug-resistant virus [13]. In March 2018, baloxavir marboxil, a new anti-influenza drug, was firstly introduced in Japan with the treatment of uncomplicated acute influenza patients within 48 h [14]. Similar to NAIs, resistant mutation (PA-I38T/M/F) to baloxavir marboxil frequently observed in patients (1.119.5%) within 35 days of treatment [15,16]. Therefore, it is important to establish an alternative antiviral method. Therapeutic monoclonal antibodies (mAbs) have become a prospective part of infectious diseases due to their specificity, limited off-target effects, and favourable safety profile. Primary examples of mAbs as treatment are palivizumab against respiratory syncytial virus and ZMapp against Ebola virus [17,18]. AIV membranes contain two major surface proteins, haemagglutinin (HA) and NA, and the majority of the neutralizing antibodies produced by vaccination or viral infection are targeted against the HA protein [19]. The mature HA protein is comprised of two disulfide-linked subunits, HA1 and HA2. The HA1 subunit constitutes the HA head domain and contains the sialic acid receptor binding site (RBS), while the HA2 subunit and a portion of HA1 form a stalk structure. The HA globular head domain mediates receptor binding and the HA stalk domain mediates host-virus membrane fusion, both of which are critical in its life cycle [20]. Antibodies target the globular HA head or a conserved site in the HA stem to anti AIVs. The anti-head antibodies are in general strain or clade specific, due to the highly variable nature of its targeted residues. The anti-stem antibodies had been shown to be extremely broad through antibody-dependent cellular cytotoxicity studies (ADCC) [21]. Here, two murine mAbs against the HA of the L67 H7N9 virus were produced and characterized,.